Skip to content
Open access · CC-BY via OpenAlex

NLRP3 inflammasome in endothelial dysfunction

Baochen Bai, Yanyan Yang, Qi Wang, Min Li, Chao Tian, Yan Liu, Lynn Htet Htet Aung, Peifeng Li, Tao Yu, Xian‐Ming Chu

Cell Death and Disease · 2020 · ▲ 475 citations

Abstract

Inflammasomes are a class of cytosolic protein complexes. They act as cytosolic innate immune signal receptors to sense pathogens and initiate inflammatory responses under physiological and pathological conditions. The NLR-family pyrin domain-containing protein 3 (NLRP3) inflammasome is the most characteristic multimeric protein complex. Its activation triggers the cleavage of pro-interleukin (IL)-1β and pro-IL-18, which are mediated by caspase-1, and secretes mature forms of these mediators from cells to promote the further inflammatory process and oxidative stress. Simultaneously, cells undergo pro-inflammatory programmed cell death, termed pyroptosis. The danger signals for activating NLRP3 inflammasome are very extensive, especially reactive oxygen species (ROS), which act as an intermediate trigger to activate NLRP3 inflammasome, exacerbating subsequent inflammatory cascades and cell damage. Vascular endothelium at the site of inflammation is actively involved in the regulation of inflammation progression with important implications for cardiovascular homeostasis as a dynamically adaptable interface. Endothelial dysfunction is a hallmark and predictor for cardiovascular ailments or adverse cardiovascular events, such as coronary artery disease, diabetes mellitus, hypertension, and hypercholesterolemia. The loss of proper endothelial function may lead to tissue swelling, chronic inflammation, and the formation of thrombi. As such, elimination of endothelial cell inflammation or activation is of clinical relevance. In this review, we provided a comprehensive perspective on the pivotal role of NLRP3 inflammasome activation in aggravating oxidative stress and endothelial dysfunction and the possible underlying mechanisms. Furthermore, we highlighted the contribution of noncoding RNAs to NLRP3 inflammasome activation-associated endothelial dysfunction, and outlined potential clinical drugs targeting NLRP3 inflammasome involved in endothelial dysfunction. Collectively, this summary provides recent developments and perspectives on how NLRP3 inflammasome interferes with endothelial dysfunction and the potential research value of NLRP3 inflammasome as a potential mediator of endothelial dysfunction.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1038/s41419-020-02985-x
Canonical
link ↗
Fetched
2026-06-08 MST

Cite this

APA
Bai, B., Yang, Y., Wang, Q., Li, M., Tian, C., Liu, Y., Aung, L.H.H., Li, P., Yu, T., &amp; Chu, X. (2020). NLRP3 inflammasome in endothelial dysfunction. <em>Cell Death and Disease</em>. https://doi.org/10.1038/s41419-020-02985-x
Vancouver
Bai B, Yang Y, Wang Q, Li M, Tian C, Liu Y, et al. NLRP3 inflammasome in endothelial dysfunction. Cell Death and Disease. 2020. doi:10.1038/s41419-020-02985-x.
BibTeX
@article{baochen2020NLRPin, title = {NLRP3 inflammasome in endothelial dysfunction}, author = {Baochen Bai and Yanyan Yang and Qi Wang and Min Li and Chao Tian and Yan Liu and Lynn Htet Htet Aung and Peifeng Li and Tao Yu and Xian‐Ming Chu}, journal = {Cell Death and Disease}, year = {2020}, doi = {10.1038/s41419-020-02985-x}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.